Anti-E. coli K99 pili [Clone K9912-418.2]

Purified E. coli K99 (B44) pili

This monoclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.2 - 7.4 with no carrier protein or preservatives added.

Liquid

Manufactured in a state-of-the-art facility located in St. Louis, Missouri USA operating under strict ISO 9001 and ISO 13485 certified quality management systems, this antibody undergoes a rigorous, multi-step purification process. Utilizing advanced Protein A or Protein G affinity chromatography, our meticulous preparation protocol ensures premium purity. This specialized processing guarantees exceptionally low levels of endotoxins, minimal leachable Protein A, and negligible aggregate formation for reliable experimental outcomes.

This antibody is stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Next Day 2-8°C

Highly selective for K99+ E. coli strains. This monoclonal antibody demonstrates zero cross-reactivity with K99-negative E. coli (B41), related fimbrial antigens (E. coli K88ac, 987P), or common bacterial pathogens including Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Enterobacter aerogenes, Citrobacter freundii, Klebsiella pneumoniae, and Streptococcus agalactiae.

Bovine enteric colibacillosis is an economically important disease in neonatal calves caused by enterotoxigenic E. coli (ETEC) which adhere to intestinal cells using pili. Most ETEC isolated from cattle use K99 pili to bind to enterocytes of the small intestine. K99 pili are primarily composed of a repeating 18.2kDa major subunit which is responsible for binding to host glycoprotein receptor, N-glycolylneuraminic acid-GM3. A 7.1kb operon of eight genes on a plasmid encode the pili and other associated proteins responsible for regulation, transport, and assembly of K99 pili.

Background for Bioprocess Monitoring and Vaccine Quality Control

The production of effective veterinary biologicals and maternal vaccines targeting neonatal calf diarrhea relies heavily on the consistent expression of the enterotoxigenic Escherichia coli (ETEC) K99 (F5) fimbrial antigen. During commercial vaccine manufacturing, precisely quantifying the expression of the 18.2 kDa FanC major subunit protein is critical for optimizing fermentation yields and ensuring regulatory batch-to-batch potency compliance.

The Leinco Technologies Anti-E. coli K99 Pili Monoclonal Antibody (Clone K9912-418.2) is an indispensable tool for biopharma quality control and downstream processing analytics. Engineered for high linear precision in quantitative immunoassays, this clone allows production scientists to accurately track K99 antigen kinetics, monitor purification efficiency, and perform critical stability testing on final veterinary vaccine formulations.